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Abstract
Background: Severe sepsis and septic shock are major causes of morbidity and mortality worldwide. In experimental sepsis
there is prominent apoptosis of various cell types, and genetic manipulation of death and survival pathways has been
shown to modulate organ injury and survival.
Methodology/Principal Findings: We investigated the effect of extracellular administration of two anti-apoptotic members
of the BCL2 (B-cell lymphoma 2) family of intracellular regulators of cell death in a murine model of sepsis induced by cecal
ligation and puncture (CLP). We show that intraperitoneal injection of picomole range doses of recombinant human (rh)
BCL2 or rhBCL2A1 protein markedly improved survival as assessed by surrogate markers of death. Treatment with rhBCL2 or
rhBCL2A1 protein significantly reduced the number of apoptotic cells in the intestine and heart following CLP, and this was
accompanied by increased expression of endogenous mouse BCL2 protein. Further, mice treated with rhBCL2A1 protein
showed an increase in the total number of neutrophils in the peritoneum following CLP with reduced neutrophil apoptosis.
Finally, although neither BCL2 nor BCL2A1 are a direct TLR2 ligand, TLR2-null mice were not protected by rhBCL2A1 protein,
indicating that TLR2 signaling was required for the protective activity of extracellularly adminsitered BCL2A1 protein in vivo.
Conclusions/Significance: Treatment with rhBCL2A1 or rhBCL2 protein protects mice from sepsis by reducing apoptosis in
multiple target tissues, demonstrating an unexpected, potent activity of extracellularly administered BCL2 BH4-domain
proteins.
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Introduction
Severe sepsis and its major complications of multiple organ
dysfunction and shock are major causes of morbidity and mortality
worldwide. Although there have been substantial improvements in
antimicrobial therapy and supportive critical care, severe sepsis
remains the leading cause of death among hospitalized patients in
non-coronary intensive care units. Unfortunately, decades of
clinical trials with a variety of drug candidates have largely failed
to reduce mortality [1,2]. Consequently, there is an urgent need to
understand better the pathophysiology of severe sepsis and identify
new therapeutic targets.
One of the hallmarks of experimental sepsis is increased apop-
tosis of a number of cell types. Although apoptosis of immune cells
has been investigated most extensively [3,4], there is also apoptosis
of other cell types [5], including endothelial cells [6,7], neutrophils
[8], hepatocytes [9], cardiomyocytes [10], and intestinal epithelial
cells [11]. Moreover, genetic manipulation of cell death and
survival pathways has marked effects in murine models of sepsis
(e.g., [12]). These observations suggest that pharmacological
inhibition of apoptosis by blocking cell death pathways or
promoting cell survival pathways could provide a new therapeutic
approach to sepsis in man [5].
BCL2 and BCL2A1 (A1, Bfl-1) are both anti-apoptotic
members of the larger BCL2 family of intracellular proteins.
Transgenic over-expression of BCL2 in T-cells and B-cells [13],
intestinal epithelium [14] and myeloid cells [15] all resulted in a
decrease in apoptosis in those cell types and improved survival in
septic mice. Thus, increased intracellular BCL2 in multiple
lineages is able to confer protection in experimental sepsis.
There is growing evidence that some proteins with well-defined
intracellular functions can exert new activities when released
extracellularly, engaging the innate immune system to act as
danger signals to promote host defense or repair, i.e., alarmins
[16] or danger-associated molecular patterns (DAMPs) [17], many
of which are hydrophobic molecules [18]. For example, high
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e14729mobility group box 1 (HMGB1) is a nucleoprotein that is released
extracellularly when cells undergo necrosis or, in some cell types,
by a non-canonical secretory pathway. High levels of HMGB1
accumulate in animals [19] and humans with severe sepsis [20,21].
Administration of antibodies against HMGB1 results in increased
survival and protection against organ damage in septic animals
[22]. However, even for this prototypic DAMP the mechanism(s)
by which it acts in vivo remains uncertain as highly purified
HMGB1 lacks significant activity in vitro [23-25]. Recently, we
reported that the intracellular BCL2 and BCL2A1 proteins and
peptides derived from them that contain the BH4-domain function
as cytoprotective DAMPs, conferring tissue protection when
administered extracellularly [26]. At very low, cytokine-like doses
extracellular administration of rhBCL2 or rhBCL2A1 protein or
peptides containing the BH4 domain of BCL2 or BCL2A1
reduced apoptosis and tissue damage in stringent murine models
of hind limb and myocardial ischemia-reperfusion injury. Further,
in preliminary studies rhBCL2A1 protein also reduced hypertro-
phy and fibrosis in pressure overload-induced heart failure [26].
Here, we show that extracellular administration of rhBCL2 or
rhBCL2A1 protein also provides striking protection in experi-
mental sepsis induced by CLP, and that this protective effect is
associated with marked reduction of apoptosis in heart, intestine,
and peritoneal neutrophils. These studies extend the range of
experimental models of tissue and organ injury in which BCL2
BH4-domain proteins exert a protective effect, further highlighting
their novel and potent extracellular activity.
Results
Treatment with extracellular rhBCL2A1 or rhBCL2 protein
improves survival after CLP
Mice were subjected to CLP and followed for 7 days as
described in Methods. An assessment table was used as a surrogate
marker for death and the animals euthanized according to
approved criteria. In the initial experiments, mice were treated
with 1 mg( ,40 picomoles) of rhBCL2A1 or saline vehicle at 18
hours prior to CLP and then every 12 hours for 3 consecutive days
for a total of eight doses. Treatment with the BH4-domain protein,
rhBCL2A1, was protective (Fig. 1A), whereas treatment with the
Figure 1. Treatment with rhBCL2A1 or rhBCL2 protein improves survival following CLP. Mice were subjected to CLP and followed for 7
days. An assessment table was used as a surrogate marker for death and the animals euthanized according to approved criteria. (A) Mice were treated
by i.p. injection of 1 mg rhBCL2A1 or saline 18 hours prior to CLP and then every 12 hours for 3 consecutive days. Treatment with rhBCL2A1 conferred
significant protection compared to saline. *p=0.012. (B) Mice were treated by i.p. injection of 1 mg rhBim or saline 18 hours prior to CLP and then
every 12 hours for 3 consecutive days. Treatment with rhBim did not improve survival compared to saline. (C) Mice were treated by i.p. injection of 1
mg rhBCL2 or 0.5 mg of rhUbiquitin at 18 hours prior to CLP, at time of CLP, and then every 12 hours for 3 consecutive days. Treatment with rhBCL2
conferred significant protection compared to rhUbiquitin *p=0.003. (D) Mice were treated by i.p. injection of 1 mg rhBCL2A1 or rhBim at 18 hours
prior to CLP and then every 12 hours for 3 consecutive days. Treatment with rhBCL2A1 conferred significant protection compared to rhBim.
*p=0.005.
doi:10.1371/journal.pone.0014729.g001
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experiments, rhBCL2A1 and rhBCL2 were compared directly
with other recombinant proteins, which had been prepared
similarly in E. coli and were also his-tagged. Treatment with the
anti-apoptotic BH4-domain BCL2 proteins conferred a significant
increase in survival, compared with treatment with the control
recombinant proteins, rhUbiquitin (Fig. 1C) or rhBim (Fig. 1D).
Consequently, rhBim was used as control in most experiments.
Treatment with extracellular rhBCL2 or rhBCL2A1 reduces
apoptosis after CLP
As compared to mice treated with rhBim (Fig. 2A, C), treatment
with rhBCL2 (Fig. 2B, D) reduced the number of TUNEL-positive
cells detected at 24 hours after CLP in the heart by 76% (Fig. 2G)
and in the intestine by 58% (Fig. 2H). Likewise, treatment with
rhBCL2A1 significantly reduced the number of TUNEL-positive
cells in the heart (Fig. 2I) and the intestine (Fig. 2F, J).
Furthermore, mice treated with rhBCL2 protein had a significant
reduction in cleaved caspase-3 expression following CLP in the
heart (Fig. 3B, F) and intestine (Fig. 3D, E) compared to mice
treated with rhBim (Fig. 3A, C, E, F). Taken together, these data
indicate that treatment with rhBCL2 or rhBCL2A1 protein
reduces sepsis-induced apoptosis in multiple target organs.
Endogenous mouse BCL2 protein is up-regulated in the
hearts and intestine of rhBCL2A1-treated mice
We next determined whether treatment with rhBCL2A1 altered
expression of endogenous BCL2. Using an anti-mouse BCL2
antibody that does not cross-react with human BCL2, we found
that mice treated with rhBCL2A1 (Fig. 4B, D) showed increased
expression of endogenous mouse BCL2 protein in both the heart
muscle and intestine, as compared to mice that were untreated or
treated with rhBim (Fig. 4A, C). We confirmed the up-regulation
of endogenous mouse BCL2 protein using flow cytometry analysis.
Cardiomyocytes from mice treated with rhBCL2A1 showed an
increase in endogenous BCL2 expression 24 hours after CLP
(Fig. 4E, F). Taken together, these data suggest that protection
may be conferred in some tissues by up-regulation of endogenous
BCL2 in the stressed tissue.
Cell populations and cytokines in peritoneum and
peripheral blood
Peripheral blood leukocyte counts were analyzed following
CLP. Mice were treated with a single i.p. injection of 1 mg
rhBCL2A1 or 1 mg of rhBim at 18 hours prior to CLP. Animals
were euthanized at 24 hours following CLP and whole blood was
analyzed. Peripheral blood leukocyte counts and neutrophil counts
were similar in rhBCL2-treated and rhBim-treated animals (total
leukocytes were 2.184610
6 +/2 0.3336 SEM in rhBim-treated
and 1.993610
6 +/2 0.4202 SEM in rhBCL2A1-treated; total
neutrophils were 0.8356610
6 +/2 0.8356 SEM in rhBim-treated
and 0.7789610
6 +/2 0.1221 SEM in rhBCL2A1-treated).
In separate experiments, leukocyte populations in peritoneal
lavage were evaluated. Mice received rhBim, rhBCL2A1, or no
treatment followed 18 hours later by CLP. Additionally, some
mice received either rhBim or rhBCL2A1, but did not have CLP.
In those animals not subjected to CLP, there was no significant
accumulation of total leukocytes or neutrophils in animals treated
with rhBCL2A1 (Fig. 5 A, B). In contrast, in animals subjected to
CLP there was a significant increase in the total number of
leukocytes in the peritoneal lavage fluid in mice treated with
rhBCL2A1 as compared to the other treatment groups (Fig. 5A).
This increase in total cells was due specifically to an increase in
neutrophils in the peritoneal lavage fluid (Fig. 5B). We did not
observe any changes in circulating neutrophil counts, and G-CSF
levels in peritoneal fluid and G-CSF mRNA expression in spleen
(Fig. S1) were similar in the rhBCL2A1-treated mice compared to
rhBim-treated mice following CLP, making it less likely that the
increase in peritoneal neutrophils following CLP was due solely to
increased production. However, annexin V-staining of peritoneal
cells showed that there were more viable neutrophils in the
peritoneal lavage of rhBCL2A1-treated animals following CLP
(Fig. 5C), consistent with a reduction in apoptosis.
We determined the generation of reactive oxygen species by
peritoneal neutrophils as determined by flow cytometry using
dihydrorhodamine-123 to detect intracellular ROS. At 24 hours
post-CLP there wasnodifferenceinROSgenerationby unstimulated
neutrophils between saline-treated mice and rhBCL2A1-treated mice
(mean channel fluorescence: 8.0764.5 in saline versus 7.0662.2 in
rhBCL2A1; means6SDof 3 mice). Similarly, there was no difference
between saline-treated and rhBCL2A1-treated following stimulation
by phorbol myristate acetate (mean channel fluorescence: 17.464.1
in saline versus 25.769.0 in rhBCL2A1; means6SD of 3 mice).
We also assayed the levels of 20 different cytokines, chemokines,
or growth factors in the peritoneal lavage fluid. Despite the
marked improvement in survival with treatment with BCL2A1,
there were no significant differences between levels in rhBCL2A1-
and rhBim-treated animals (Table S1).
Protection by rhBCL2A1 requires TLR2 signaling
Although rhBCL2 and rhBCL2A1 are not direct TLR2 agonists
or antagonists in vitro [26], we recently demonstrated that
protection against ischemia-reperfusion injury of hind limb by
rhBCL2A1 required TLR2 and signaling in vivo as evidenced by
lack of protection in TLR2-null or MyD88-null mice [26].
Consistent with these results in ischemia-reperfusion injury,
treatment with rhBCL2A1 did not protect TLR2-null mice
following CLP (Fig. 6).
Discussion
There is compelling experimental evidence that apoptosis is a
major contributor to the multiple organ dysfunction in experi-
mental sepsis [5]. Among the genes related to apoptosis, BCL2
and family members are the most extensively investigated
[reviewed in [27]]. In multiple studies transgenic mice over-
expressing BCL2 in various target cells have decreased apoptosis
and improved survival in sepsis [13,15,28,29]. In a recent study we
showed that extracellular administration of rhBCL2 or rhBCL2A1
protein provided protection in murine models of hind limb and
cardiac ischemia [26]. In the present study, we demonstrate that
exogenous administration of rhBCL2 or rhBCL2A1 protein
reduces apoptosis in heart, intestine, and peritoneal neutrophils
and improves survival following CLP-induced sepsis. We previ-
ously showed that BCL2 is released extracellularly with cell
necrosis in vitro [26]. In this regard, it is notable that Hotchkiss et al
[30] reported that administration of necrotic cells improved
survival in CLP-induced sepsis. Further, since BCL2 and BCL2A1
are expressed on the plasma membrane in some cells [31,32], it is
also possible that BH4-domain proteins are shed during activation
or apoptosis as occurs with other plasma membrane proteins.
Notably, soluble BCL2 has been detected in extracellular fluids in
a variety of clinical conditions [33-37]. Thus, BCL2 and BCL2A1
join a growing list of alarmins or DAMPs that modulate the
response of the innate immune system to tissue injury [16,17].
However, in contrast to many other alarmins or DAMPs, BCL2
and BCL2A1 do not appear to elicit a pro-inflammatory response
BCL2 Protein in Sepsis
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e14729Figure 2. Treatment with rhBCL2 or rhBCL2A1 reduces apoptosis in intestine and myocardium following CLP. Animals were treated
with a single i.p. injection of 1 mg rhBim or rhBCL2 or rhBCL2A1 at 18 hours prior to CLP. Tissues were removed and processed at 24 hours following
CLP. In the photomicrograph (A-F) TUNEL-positive cells are labeled with FITC (green) and nuclei are labeled with DAPI (blue). Panels A and B shows
myocardium from mice treated with rhBim (A) or rhBCL2 (B). Panels C-F show intestinal villi from mice treated of rhBim (C, E), rhBCL2 (D) or rhBCL2A1
(F). The graph shows quantitation of TUNEL-staining in cardiomyocytes (G, I) or intestine (H, J) following treatment with rhBim or rhBCL2 (G, H) or
rhBCL2A1 (I, J). The number of TUNEL-positive cells in mice treated with rhBim was significantly greater than in mice treated with rhBCL2 or
rhBCL2A1. *p,0.05.
doi:10.1371/journal.pone.0014729.g002
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analyzed 69 serum proteins following intravenous administration
of BCL2A1 protein and found no significant changes from
baseline (Table S2).
In preliminary experiments we sought to determine whether
treatment following induction of CLP might still be protective. As
shown in Fig. S2, treatment at 24 hours after CLP was not
effective. However, it is important to note that this is a highly
lethal model of sepsis with many animals succumbing within the
first 24–48 hours. Consequently, it is likely that many of the
animals are already not salvageable by 24 hours. To definitively
address the question as to whether post-treatment would be
effective would require establishing a less stringent model of sepsis
in which the early mortality was not as marked.
Animals treated with rhBCL2- or rhBCL2A1 exhibited reduced
numbers of TUNEL-positive cells as well as decreased caspase-3
expression in cardiomyocytes and intestinal cells following CLP,
suggesting that improved survival may be due, at least in part, to a
reduction of apoptosis in multiple organs. Interestingly, the decreased
apoptosis in the rhBCL2A1-treated animals was associated with
increased expression of endogenous mouse BCL2 protein in heart and
intestinal cells as determined by both immuno-cytochemistry and flow
cytometry. Also, there was a significant increase in the total number of
neutrophils in the peritoneal lavage fluid from mice receiving
rhBCL2A1 followed by CLP, which was likely due to a reduction in
neutrophil apoptosis as evidenced by decreased annexin-V staining.
This early increase in neutrophils at t h es i t eo fi n f e c t i o nm i g h ts e r v et o
contain the infection, consequently improving survival. Since murine
neutrophils express BCL2A1 but not BCL2, it sees likely that
protection by BCL2 or BCL2A1 protein involves up-regulation of
other cytoprotective genes (or down-regulation of pro-apoptotic genes).
The endoplasmic reticulum (ER) stress pathway or unfolded
protein response (UPR) is one potential target for extracellular
BCL2 or BCL2A1 protein [38]. Sepsis [39] and I/R [40] have
both been shown to activate the ER stress response and
modulation of the response reduces apoptosis in these models. In
previous studies we showed that the BH4-domains of BCL2,
BCL2A1, and BCL-Xl were protective [26]. Extracellular BCL2
Figure 3. Treatment with rhBCL2 protein reduces cleaved caspase-3 in heart and intestine of mice following CLP. Mice were treated
with a single i.p. injection of 1 mg rhBim (A, C) or 1 mg rhBCL2 (B, D) at 18 hours prior to CLP. Heart (A, B) or intestine (C, D) was stained for cleaved
caspase with 3, 39-diaminobenzidine (brown). Nuclei were stained with hematoxylin (purple). Original magnification is 4006. Panels E and F show
quantitation of cleaved caspase-3 expression in myocardium (E) and intestinal villi (F) in mice treated with rhBim compared to those treated with
rhBCL2. *p,0.05.
doi:10.1371/journal.pone.0014729.g003
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e14729Figure 4. Treatment with rhBCL2A1 increases expression of endogenous BCL2 following CLP. Mice were treated with a single i.p.
injection of 1 mg rhBim (A, C) or rhBCL2A1 (B, D) at 18 hours prior to CLP. Heart (A, B) and intestine (C, D) were examined at 24 hours following CLP.
Endogenous mouse BCL2 protein was detected by immuno-staining with rabbit anti-mouse BCL2 antibody detected with 3, 39-diaminobenzidine
(brown) and the nuclei were stained with hematoxylin (purple). Representative FACS analysis of endogenous BCL2 expression in cardiomyocytes from
mice treated as above with rhBim (E) or rhBCL2A1 (F). Green line represents isotype control and red line represents anti-mouse BCL2 antibody.
doi:10.1371/journal.pone.0014729.g004
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stress response by binding to and signaling through a receptor such
as a cell surface Bax inhibitor-1 (BI-1) family member [40-42] or
membrane voltage–dependent anion channel (VDAC) [43]. BCL2
or BCL2A1 protein could internalize and bind to ER BI-1 or
1,4,5-inositol trisphosphate receptor (I3PR) [44] to suppress an ER
stress. BCL2A1 binding to VDAC may also impact ER-triggered
mitochondrial membrane permeabilization [45]. In preliminary
studies, we have observed uptake of extracellularly administered
rhBCL2 protein by neutrophils in vivo (Fig. S3, A, B) and by cells in
vitro (Fig. S3, C-F). Further, we have also demonstrated binding of
a biotinylated-BH4-BCL2 peptide to cells in vitro (Fig. S4). Future
studies should identify the plasma membrane or intracellular
target(s) of the extracellularly administered BCL2 proteins.
As previously reported for ischemia-reperfusion injury [26], we
found that administration of rhBCL2A1 failed to protect TLR2-
null mice from sepsis-induced mortality, indicating that there is a
requisite role for TLR2 signaling for the protective effect in vivo.
However, neither rhBCL2 nor rhBCL2A1 is a direct TLR2 ligand
as assessed by IL-8 production in HEK cells transfected with
TLR2/6 or by activation of NF-kB in the THP1 macrophage cell
line [26]. Also, the response of THP1 macrophage cells to several
TLR2 and TLR4 ligands was unaffected by pretreatment with
rhBCL2A1 [26]. As discussed previously [26], there are several
potential explanations for the discrepancy between the in vivo
dependence on TLR2 signaling and the lack of direct TLR
signaling in vitro results with respect to TLR2. First, there may be
an intermediate effector cell(s) in vivo that elaborates an endo-
genous TLR2 ligand(s) in response to stimulation by rhBCL2A1 or
rhBCL2. Second, BCL2 or BCL2A1 may require a co-factor for
activity in vivo as has been described for the prototypic DAMP,
HMGB1, which lacks significant activity in vitro when it is highly
purified [23-25], but acquires activity upon binding to other TLR
ligands [25] or cytokines [24]. Third, since TLR2 heterodimerizes
with TLR1 and TLR6 and TLR2 signaling is modulated by
several non-TLR receptors [46-48], it is possible that signaling in
response to rhBCL2 or rhBCL2A1 protein involves a co-receptor
and that co-operative signaling by this receptor and TLR2 is
responsible for cytoprotection in vivo. Fourth, A1 may prime cells
for a TLR2 response to oxidized lipoproteins produced during
ischemia [49]. Significantly, TLR2 signaling has recently been
shown to suppress the ER stress response [50].
Figure 5. Treatment with rhBCL2A1 increases neutrophils in
peritoneum following CLP. Mice were treated once by i.p. injection
with 1 mg of rhBCL2A1 or rhBim at 18 hours prior to CLP. Peritoneal
lavage fluid was collected at 24 hours following CLP. Panels A and B
show the total number of leukocytes and neutrophils (PMNs) in lavage
fluid. Mice treated with rhBCL2A1 showed an increase in peritoneal
PMNs following CLP as compared to mice that did not receive CLP or
mice that were treated with rhBim. Panel C shows the viability of
peritoneal neutrophils at 24 hours following CLP as assessed by staining
with annexin V and 7-amino-actinomycin D. Treatment with rhBCL2
significantly increased the number of viable neutrophils compared to
treatment with saline or rhBCL2A1. *p,0.01.
doi:10.1371/journal.pone.0014729.g005
Figure 6. Treatment with rhBCL2A1 does not protect TLR2-null
mice. C57BL/6 or TLR2-null mice were subjected to CLP and followed
for 7 days. An assessment table was used as a surrogate marker for
death, and the animals were euthanized according to approved criteria.
Animals were treated by i.p. injection of saline or 1 mg rhBCL2A1 at 18
hours prior to CLP, at the time of CLP, and then every 12 hours for the 3
consecutive days. There was no significant difference in survival
between the treatment groups.
doi:10.1371/journal.pone.0014729.g006
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rhBCL2 or rhBCL2A1 protein provides substantial protection in
CLP-induced sepsis in mice. Although the precise cellular and
molecular pathways involved in the extracellular activity of BCL2
and BCL2A1 remain to be elucidated, the protective effect is
associated with a reduction in apoptosis in the intestine and heart,
increased expression of endogenous BCL2 in epithelial cells and
cardiomyocytes, and increased neutrophil accumulation in perito-
neum. Given that the BCL2 BH4-domain proteins themselves do
not appear to elicit a pro-inflammatory response [26](Table S2), as
is observed with many other DAMPs, it is possible that
extracellular administration of rhBCL2 or rhBCL2A1 protein
may offer a new approach to therapy of sepsis.
Materials and Methods
Mice
All protocols were approved by the Animal Care and Use
Committee of the University of Washington (IACUC #2234-10,
08/05/2009) and complied with the NIH guidelines for care and
use of animals. Mice were maintained at the University of
Washington, Department of Comparative Medicine facility.
C57BL/6 mice were obtained from Charles River Breeding
Laboratory (Wilmington, MA). TLR2-null on C57BL/6 back-
ground were bred in the animal facility at the University of
Washington. Breeding pairs were a gift of Dr. S. Akira (Osaka,
Japan).
Reagents
rhBCL2, rhUbiquitin, rhBim, and rhBCL2A1 were purchased
from R&D Systems (Minneapolis, MN). rhBCL2 protein consisted
of amino acids 1-212 (accession number P10415) of human BCL2
with the carboxyl terminus replaced with a ten histidine tag.
rhBCL2A1 protein consisted of amino acids 1-152 of human
BCL2-related protein BCL2A1 (accession number NP004040)
missing the carboxyl terminal hydrophobic domain, which was
replaced with a six histidine tag. rhUbiquitn consisted of amino
acids 1-76 (accession number CAA28495.1) containing the amino
acids ATVID followed by a 10 histidine tag at its amino terminal.
rhBim consisted of amino acids 2-120 (accession number
AAC39594) of human Bim long with a deleted carboxyl terminal
transmembrane domain replaced with a six histidine tag. Purity of
the proteins was .95% for the recombinant proteins as
determined by SDS-PAGE and visualized by silver stain per
manufacturer (R&D Systems). In addition, endotoxin concentra-
tion in the recombinant proteins was less than 0.15 EU/mg
protein (R&D systems).
Cecal ligation and puncture
Mice were anesthetized with halothane, an abdominal midline
incision made and the cecum was gently removed and ligated
below the ileocecal valve without obstruction of the ileum or colon.
The cecum was then subjected to a single ‘through and through’
perforation with a 20-gauge needle and a small amount of cecal
contents gently expressed through the needle wound. The bowel
was carefully returned to its original position, and then the
abdominal incision was closed in layers with 4-0 sutures.
Survival after CLP
Mice were followed for up to 7 days after CLP. Each animal was
scored using an assessment form that evaluated each animal’s
health as described by Morton and Griffiths [51], and the animal
was euthanized if it exceeded a predetermined score indicative of
irreversible sepsis. All animals received 0.5 mg of imipenem in
1.0 ml of 5% dextrose in water 2 hours after CLP. Additional
doses of 0.5 mg/mouse of imipenem in 1.0 ml of 5% dextrose in
water were given twice a day for 4 days. Mice were treated with
rhBCL2A1, rhBCL2, rhBim or rhUbiquitin as indicated.
TUNEL assay
Mice were sacrificed 24 hours after CLP, and their heart and
entire intestine were removed. The intestine was opened along the
length of its cephalocaudal axis and washed in 4% neutral-
buffered formalin to removed lumenal contents. The tissue was
rolled from the proximal to the distal end and fixed with 10%
neutral-buffered formalin. Paraffin-embedded sections from heart
and intestine were examined for DNA strand breaks by TUNEL
(In Situ Cell Death Kit, Roche Molecular Biochemicals) as
described by the manufacturer.
Immunocytochemistry
Tissue sections were pre-treated by boiling in citrate buffer
(pH 6.0) in a microwave oven. Immunocytochemistry was
accomplished using rabbit anti-mouse BCL2 polyclonal antibody
(Upstate, Waltham, MA), or an antibody recognizing active
caspase-3 (Cell Signaling, Beverly, MA) using a Vectastain ABC
elite kit (Vector Labs, Burlingame, CA), and 3, 39-diaminobenzi-
dine (Vector Labs) as a chromagenic substrate with hematoxylin
counterstaining.
Quantitation of Images
Images were acquired using a Nikon Labphot microscope with
Nikon Plan Fluor 20 Ph3DL (numerical aperture: 0.75) objective
(Nikon Instruments, Inc, NY) and Spot v.3.5.9 (Diagnostic
Instruments Sterling Heights, MI) digital imaging system. The
images from the tissue stained for mBCL2 were opened in
Photoshop (Adobe Systems Inc. San Jose, CA), and staining
intensity was determined by luminosity of the image with no
alteration to the original image.
Leukocytes and cytokines in peritoneal lavage fluid and
peripheral blood
Peritoneal lavage fluid was collected from mice 24 hours after
CLP as described previously [15]. The total number of cells and
percent of subpopulations in peritoneal lavage fluid were also
determined as previously described [15]. The concentration of
cytokines in the peritoneal lavage fluid was determined using a
mouse cytokine twenty-plex according to manufacturer’s protocol
(Invitrogen, Multiplex Kit #LMC0006). The numbers of various
cell populations in whole blood were determined using a
HEMAVET 950 (Drew Scientific Inc., Dallas, TX).
Assessment of neutrophil viability in peritoneal lavage
fluid
Peritoneal neurtophils were collected by lavage, and contam-
inating fecal debris was removed by filtering through 100 mm
filters. Cells were washed with PBS-1%FBS and resuspended in
PBS-1%FBS for determination of cell counts. Cell viability was
assessed using annexin V apoptosis detection kit (BD Biosciences,
San Jose, CA) containing annexin V-PE and. 2610
5 cells in 100 ml
of binding buffer were incubated with 2 ml of annexin V-PE and 2
ml of 7-amino-actinomycin D for 15 min at 25 uC in the dark. Flow
cytometry analysis was performed on a BD FACScan. Live cells
were defined as staining negatively for both annexin V and 7-
amino-actinomycin D. Flow cytometry data was analyzed with
CellQuest software (BD Biosciences). Data are presented as
percentage of live cells in each treatment group.
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We prepared single cell suspensions of cardiomyocytes from
hearts harvested 24 hours after CLP as follows. Mice received an
injection of heparin (5000 U/kg, ip.) 10 minutes prior to euthansia
by exsanguination by cardiac puncture under anesthesia. The
animal’s chest was opened, heart exposed, and the aorta
cannulated with a 24-guage angio-catheter. The heart was
perfused with 3 ml of perfusion buffer (AfCS Procedure Protocol
PP00000125), followed by perfusion with a digestion buffer
(collagenase type II, 75 U/mL, trypsin, 0.14 mg/ml, CaCl2, 1.5
in perfusion buffer) for 20 minutes at 0.5 ml/min. The hearts were
placed into a petri dish containing the digestion buffer and
manually cut into small pieces. The tissues were transferred to
15 ml tubes in stop buffer (10% BCS, 12.5 mM CaCl2 in perfusion
buffer) and further dissociated by triturating using a Pasteur
pipette. The samples were centrifuged, the supernatant removed
and transferred to a 60 mm petri dish. Calcium was adjusted to a
final calcium concentration of 1 mM by adding CaCl2. A single
cell suspension was prepared by passing the samples through a
40 mm mesh filter. Cells were fixed (BD Cytofix Buffer) for
30 minutes at 4 uC, washed and incubated overnight with the
primary antibody to mouse BCL2 or isotype control (BD
Pharmingen 556537) at 4 uC. The following day, the cells were
washed, resuspended in FACS buffer, and analyzed by FACScan.
Determination of Reactive Oygen Species generation
Three ml of peritoneal fluid were obtained from each mouse at
24 hours post-CLP. Leukocytes were obtained by centrifugation
and lysis of red cells. Equal numbers of leukocytes were loaded
with 5 mM DHR123 (Molecular Probes, Eugene, OR) and
washed. Cells were resuspended in RPMI medium containing 2%
serum. After a15 min incubation at 37 uC with or without 100 ng/
ml phorbol myristate acetate (PMA) (Sigma-Aldrich, ST. Louis,
MO), cells were removed to ice and fixed with formaldehyde
(Polysciences, Inc., Warrington, PA). Flow cytometry data were
acquired on a FACScan (Becton-Dickinson, San Jose, CA) and
analyzed using CELLQuest software (BD).
Statistical analysis
The data are presented as the means 6 standard error of the
mean. Statistical analysis was performed using the two-tailed t-test
(GraphPad Prism). Survival curves were analyzed by logrank test
(GraphPad Prism). Differences associated with a value of p,0.05
were considered statistically significant.
Supporting Information
Table S1 Treatment with rhBCL2A1 does not alter cytokine,
chemokine, or growth factor levels in peritoneal lavage fluid
following CLP.
Found at: doi:10.1371/journal.pone.0014729.s001 (0.04 MB
DOC)
Table S2 Plasma analytes after injection of rhBCL2A1 in rats
Found at: doi:10.1371/journal.pone.0014729.s002 (0.18 MB
DOC)
Figure S1 G-CSF levels in spleen and peritoneal fluid following
CLP. Mice were treated with 1 mg of rhBCL2A1 or saline on the
day prior to and at time of CLP. Spleen and peritoneal lavage fluid
were collected at 24 hrs after CLP. G-CSF expression levels were
determined in spleen by RT-PCR using primer probes and
7900HT system from Applied Biosystems. Mouse G-CSF protein
was determined in the peritoneal fluids using a single analyte
ELISA kit (SABiosciences Corporation, Frederick, MD) according
to the manufacturer’s instructions. *p=0.049 by unpaired t-test.
Found at: doi:10.1371/journal.pone.0014729.s003 (2.19 MB TIF)
Figure S2 Treatment with rhBCLA1 at 24 hours following CLP.
Animals were subjected to CLP with no pretreatment. At 24 hours
after CLP mice were given 10 mg rhBCLA1 by i.p. injection or
saline vehicle control and then treated with 1 mg rhBCL2A1 or
saline every twice daily for next 3 days for a total of seven
doses.
Found at: doi:10.1371/journal.pone.0014729.s004 (6.45 MB TIF)
Figure S3 Uptake of rhBCL2 by rodent cells in vivo and in vitro.
In vivo: A rat was treated with 20 mg of rhBCL2 protein given by
i.p. injection and at one hour after treatment peripheral blood was
collected and leukocytes were isolated following lysis of red cells.
Immuno-staining for hBCL2 was performed using an anti-hBCL2
antibody (BD Pharmingen #554231), which does not cross-react
with the rodent protein. (A) A preparation of peripheral blood rat
leukocytes is shown in low magnification with nuclei counter-
stained with DAPI (blue). (B) ,5% of rat neutrophils showed
immuno-staining for hBCL2 protein as shown in the confocal
microscopic image (original magnification: 6600). In vitro:
JAWSII dendritic cells were incubated with medium containing
2 mg/ml hBCL2 protein for 4 (D) or 24 hours (E, F). In (C) cells
were incubated with isotype-control antibody. (D) After four hours
incubation prominent immuno-staining for hBCL2 was observed
in cytoplasm (original magnification 6400). (E, F) After 24 hours
incubation, immuno-staining for hBCL2 was still observed but was
not as prominent as at 4 hours. (original magnification: E,6100; F,
6400).
Found at: doi:10.1371/journal.pone.0014729.s005 (4.48 MB TIF)
Figure S4 Binding of BH4-BCL2 peptide to cell surface in vitro.
The binding of biotinylated-BH4-BCL2 peptide (SynPep, Dublin
CA), scrambled biotinylated-sBH4-BCL2 peptide, and biotiny-
lated-BH3-Bax peptide to JAWS2 dendritic cells grown in (A)
suspension or (B) adherent was assessed after incubation for 30
minutes at 4C. Binding was determined by subsequent binding of
phycoerythrin-strepavidin and flow cytometry.
Found at: doi:10.1371/journal.pone.0014729.s006 (2.33 MB TIF)
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